Not nice enough.

The third-generation EGFR-TKI osimertinib pulled out a big victory last month in demonstrating an improvement in the golden egg of overall survival when compared to other EGFR-TKIs as first-line treatment for advanced non-small cell lung cancer (NSCLC). Well that hasn’t kept NICE, the ultimate arbitrator of healthcare coverage in the UK, from dictating that gold isn’t worth the incremental cost over the competition. | NICE 2020